…rmaceuticals and has also contributed to the activities in each of the other sectors. Ron is currently on the boards of Durata Therapeutics (NASDAQ: DRTX), IlluminOss Medical, Relypsa (NASDAQ: RLYP), and SpineWave. Ron was previously on the boards of Cerexa (NLV-I company acquire...
Results for “Durata Therapeutics”
Search across the indexed text of every released document.
Names that match “Durata Therapeutics”
46 documents found
Sprout Capital IX, L.P. (Healthcare Technology Portfolio) $ amounts in millions, as of March 31, 2014 Please refer to Endnotes 1,],K,L,M and N in this Appendix. Gross Multiple Total Value Realized Unrealized Value Value Total Cost Vintage Company Sector Year Portion) Gross...
Sprout Capital VIL, L.P. (Healthcare Technology Portfolio) $ amounts in millions, as of March 31, 2014 Please refer to Endnotes 1,],K,L,M and N in this Appendix. Gross Multiple Gross Vintage Total Realized Unrealize Total (Realized Multiple Company Year Cost Value d Value Valu...
…rmaceuticals and has also contributed to the activities in each of the other sectors. Ron is currently on the boards of Durata Therapeutics (NASDAQ: DRTX), IlluminOss Medical, Relypsa (NASDAQ: RLYP), and SpineWave. Ron was previously on the boards of Cerexa (NLV-I company acquire...
…YP), Convergence/Calchan Pharmaceuticals (NLV-IL, one start up that subsequently split to become 2 separate companies), Durata Therapeutics (NLV-II: IPO - July, 2012, NASDAQ: DRTX), and Ilypsa (Sprout IX, exited in sale to Amgen, 6.9x multiple). e Established Private Companies:...
James Niedel, MD, Ph.D., (70), Venture Partner, joined Sprout in May 2002 and helped found New Leaf in 2005. Jim will change his status to Venture Partner in NLV-II] with the closing of the new fund. In this role, Jim will work full-time as a senior member of the NLV investment t...
From: Steven Victor MD 111.11111..... Sent: 11/23/2012 1:06:38 PM To: CC: Subject: Report on Stem Cells future PUBLISHED: 22 NOVEMBER 2012 The view from the US: Stem cell therapy steps up a gear with first approval and improved political climate Special Report Peter Winter Positi...
Through its Common Fund the NIH has established the Center for Regenerative Medicine (NIH CRM), to support this field, with the goal of accelerating the translation of stem cell-based clinical therapies. State funding filling the void With stem cell research in general not attr...
ACKRELL CAPITAL Cannabis Investment Report | December 2017 Toronto Stock Exchange ($U.S. millions, except stock price) LTM Forward Forward EV Revenue EBITDA Stock % Below . : . Price 52-Week Market Enterprise LTM LTM Multiples __Muttiples Multiples Company Ticker 11/30/17 Hi...
Journal of Medicine editorial (November 2013), where Janet Woodcock, MD, the FDA’s Director of the Center for Drug Evaluation and Research and other senior FDA staff members as co-authors, discussed the FDA’s new breakthrough therapy designation that can be granted to expedite th...
New Leaf has not created a formal advisory board for therapeutics
Inc. Therapeutics 7.7 19.4 - 19.4 2.51 2.51 581.9%
Inc. Therapeutics 2013 10.4 11.1 - 11.1 1.06 1.06 13.1%
Inc. Therapeutics 2011 20.6 27.0 44.9 71.9 3.07 3.50 57.7%
Inc. Therapeutics 2013 3.4 6.8 - 6.8 2.03 2.03 1583.0%